China
Africa
Explore chapters and articles related to this topic
Mass in the Epigastrium
Published in K. Gupta, P. Carmichael, A. Zumla, 100 Short Cases for the MRCP, 2020
K. Gupta, P. Carmichael, A. Zumla
Five conditions have to be excluded: Carcinoma of the stomach.Carcinoma of the transverse colon.Aneurysm of the abdominal aorta.Pancreatic tumour or pseudocyst.Retroperitoneal lymphadenopathy.
Mahvash Disease
Published in Dongyou Liu, Handbook of Tumor Syndromes, 2020
The most common presenting symptom is abdominal pain or discomfort. Some patients may be asymptomatic, with a pancreatic tumor incidentally found by imaging performed for other reasons. Other symptoms may include weight loss, mild hypoglycemia, constipation or diarrhea, fatigue, recurrent pancreatitis, polyuria, and polydipsia.
The pancreas
Published in Professor Sir Norman Williams, Professor P. Ronan O’Connell, Professor Andrew W. McCaskie, Bailey & Love's Short Practice of Surgery, 2018
Professor Sir Norman Williams, Professor P. Ronan O’Connell, Professor Andrew W. McCaskie
Endoscopic ultrasound (EUS) is performed using a special endoscope that has a high-frequency ultrasonic transducer at its tip. When the endoscope is in the lumen of the stomach or duodenum, the pancreas and its surrounding vasculature and lymph nodes can be assessed (Figure68.20). This is particularly useful in identifying small tumours that may not show up well on CT or MRI, and in demonstrating the relationship of a pancreatic tumour to major vessels nearby. EUS can clarify the relationship of a neuroendocrine tumour to the main pancreatic duct (important if enucleation is being considered).
A detailed insight of the tumor targeting using nanocarrier drug delivery system
Published in Drug Delivery, 2023
Sibgha Batool, Saba Sohail, Fakhar ud Din, Ali H. Alamri, Ahmad S. Alqahtani, Mohammad A. Alshahrani, Mohammed A. Alshehri, Han Gon Choi
Inspite of a very low incidence rate (approximately 3%), pancreatic tumor is still regarded as fourth major cause of cancer deaths among both genders in United States. The prevalence of pancreatic tumor is higher (50%) in men than in women. It usually affects adults, with cases arising in 60–80 years old patients (R. Hruban, 2010). Pancreatic tumor is associated with very low survival rates, i.e. 5–7% per 5 years (Adiseshaiah et al., 2016) . Average survival rates are 6–10 months and 3–6 months for localized pancreatic tumor and metastatic pancreatic tumor respectively. Several factors are responsible for low survival rate, mainly the end stage diagnosis. Moreover, most of the patients did not show any symptom until the disease progress to a metastatic stage. About 10% of the patients suffering from pancreatic cancer are eligible for initial resection (Gillen et al., 2010). Numerous risk factors for pancreatic tumor have been identified such as familial basis (R.H. Hruban et al., 2010), smoking (Iodice et al., 2008), pancreatitis (Raimondi et al., 2010), and diabetes mellitus (Bosetti et al., 2014), but currently there is no tool for screening patients with greater risk.
Evaluation of endoscopic ultrasound-guided fine-needle biopsy for preoperative pancreatic solid lesions
Published in Scandinavian Journal of Gastroenterology, 2021
Akashi Fujita, Shomei Ryozawa, Yuki Tanisaka, Tomoya Ogawa, Masahiro Suzuki, Hiromune Katsuda, Tomoaki Tashima, Ryuichiro Araki, Masafumi Mizuide
First reported in 1992 [3], endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is well established worldwide, providing consistent results for pancreatic solid lesions under ultrasound guidance [4,5]. For detecting solid pancreatic lesions, the sensitivity and specificity of EUS-FNA are approximately 85%–89% and 96%–99%, respectively [4,6,7]. Although complications such as pancreatitis and bleeding may occur, EUS-FNA is overall very safe, with <1% morbidity and mortality rates [8,9]. Therefore, this modality has been utilized for the preoperative diagnosis of pancreatic tumor. However, the need for needle selection, rapid on-site evaluation (ROSE), and skilled endoscopists remains to be a controversial issue for EUS-FNA [10].
Pancreatic ablation: minimally invasive treatment options
Published in International Journal of Hyperthermia, 2019
Daniele Maiettini, Giovanni Mauri, Gianluca Varano, Guido Bonomo, Paolo Della Vigna, Alberto Rebonato, Franco Orsi
Pancreatic tumor remains a challenging issue in the medical field. Despite the improvements that are occurring in last years in all clinical fields, pancreatic cancer is still burdened by poor prognosis and the gold standard for treatment when possible is surgery [1]. Unfortunately, less than 20% of patients is eligible for pancreatectomy at the diagnosis; the remaining patients are treated with systemic therapy that leads anyway to a 5-years survival less than 5% [2]. These assumptions drove research efforts to find other approaches to support systemic therapy such as radiotherapy [3] or other minimally invasive procedures [4].